Intellia Therapeutics (NTLA) EBT (2016 - 2025)
Historic EBT for Intellia Therapeutics (NTLA) over the last 11 years, with Q3 2025 value amounting to -$104.8 million.
- Intellia Therapeutics' EBT rose 2102.18% to -$104.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$445.4 million, marking a year-over-year increase of 874.79%. This contributed to the annual value of -$486.5 million for FY2024, which is 451.1% down from last year.
- Intellia Therapeutics' EBT amounted to -$104.8 million in Q3 2025, which was up 2102.18% from -$102.6 million recorded in Q2 2025.
- In the past 5 years, Intellia Therapeutics' EBT registered a high of -$46.2 million during Q1 2021, and its lowest value of -$143.7 million during Q1 2022.
- Over the past 5 years, Intellia Therapeutics' median EBT value was -$104.7 million (recorded in 2022), while the average stood at -$104.6 million.
- As far as peak fluctuations go, Intellia Therapeutics' EBT crashed by 21101.83% in 2022, and later skyrocketed by 3042.88% in 2023.
- Over the past 5 years, Intellia Therapeutics' EBT (Quarter) stood at -$79.9 million in 2021, then plummeted by 31.06% to -$104.7 million in 2022, then dropped by 21.67% to -$127.4 million in 2023, then rose by 1.27% to -$125.8 million in 2024, then rose by 16.73% to -$104.8 million in 2025.
- Its EBT was -$104.8 million in Q3 2025, compared to -$102.6 million in Q2 2025 and -$112.2 million in Q1 2025.